Effects of Single-Dose Nicotinamide Riboside (NR) on Sleep

What Was Tested

The trial (not phased) is built around NAD+.

In this randomized, double-blind, placebo-controlled study, 28 healthy adults will complete two overnight sleep assessments using polysomnography (PSG), the gold-standard sleep monitoring method.

It had two arms (groups): Nicotinamide Riboside (NR) Group (experimental) and Placebo Group (placebo comparator).

The registry classes the interventions as dietary supplement and other.

More on the Plan

Sleep quality is a major component of overall health, yet many adults experience mild but persistent sleep difficulties.

Nicotinamide riboside (NR) is a naturally occurring precursor of NAD+, a key coenzyme involved in cellular energy metabolism and circadian regulation.

This study is designed to explore the acute impact of NR on sleep in healthy adults with mild subjective sleep complaints.

It uses a randomized, double-blind, placebo-controlled design to minimize bias.

Who Took Part

Enrollment: 28 actual participants took part.

It was open to people of any sex aged from 18 years up to 60 years.

Healthy volunteers could join, not only people with the condition.

Examples of who could join: Healthy males or females aged 18 to 60 years inclusive;. Screening using the Pittsburgh Sleep Quality Index (PSQI) scale with a total score between 5 and 10, indicating mild subjective sleep disturbance;. Voluntarily participate in this study and sign a written informed consent form;. Able to understand the study procedures and willing to comply with all laboratory regulations.

The full record lists 4 inclusion and 7 exclusion criteria; among the exclusions: history of any serious neurological, cardiovascular, respiratory, hepatic, renal, hematological, or psychiatric disorders;; medically diagnosed sleep disorders (e.g., insomnia, sleep apnea syndrome, restless legs syndrome);; regular use within the past month of any medication or supplement that may affect sleep (e.g., sedatives, antidepressants, antihistamines, melatonin);.

How the Study Was Run

It was run as a randomized, parallel-group and quadruple-blind study.

Because people in this NAD+ study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

The NAD+ group and the comparison group ran side by side rather than switching.

Blinding on both sides kept the participants and researchers unaware of who received NAD+.

Those kept unaware of assignments: participant, care provider, investigator and outcomes assessor.

It started in 2025-12-17 with completion listed for 2026-08-30.

It ran at 1 site in China.

Its stated primary purpose is basic science.

What Was Measured

The main thing measured (primary outcome): Change in N3 Sleep Duration (time frame: Night 1 and Night 2).

It also tracked 10 secondary outcomes, for example Change in Total Sleep Time, Change in Sleep Efficiency, Change in Sleep Onset Latency, Change in Wake After Sleep Onset, Change in Arousal Frequency and Change in N1 Sleep Duration.

What This Means in Plain Language

Put simply, this is a not phased, randomized trial of NAD+ in 28 people.

Its size is small, so on its own it can only give an early look.

The trial is marked completed; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the NAD+ compound page, all human trials.